563 related articles for article (PubMed ID: 9791142)
1. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
3. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
[TBL] [Abstract][Full Text] [Related]
4. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
5. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Descamps D; Flandre P; Calvez V; Peytavin G; Meiffredy V; Collin G; Delaugerre C; Robert-Delmas S; Bazin B; Aboulker JP; Pialoux G; Raffi F; Brun-Vézinet F
JAMA; 2000 Jan; 283(2):205-11. PubMed ID: 10634336
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
[TBL] [Abstract][Full Text] [Related]
9. A trial of three antiretroviral regimens in HIV-1-infected children.
Luzuriaga K; McManus M; Mofenson L; Britto P; Graham B; Sullivan JL;
N Engl J Med; 2004 Jun; 350(24):2471-80. PubMed ID: 15190139
[TBL] [Abstract][Full Text] [Related]
10. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Gartland M;
Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
[TBL] [Abstract][Full Text] [Related]
11. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
13. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
[TBL] [Abstract][Full Text] [Related]
14. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
17. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
20. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
